Gene Therapy for Genetic Skin Disease Is No Longer Theoretical
A gene therapy you squeeze out of a tube and a sheet of gene-corrected skin you suture onto a wound are both approved medicines now — and skin turned out to be the easiest place in the body to try this.
Read the preview
Could a gene therapy come in a tube? It already does. On wounds from a genetic blistering disease, it healed two-thirds completely at six months, against about a fifth on placebo, in the same patients. Skin lets one person carry treated and untreated wounds side by side. But the trials measured wounds, not the disease — so what now? The Dermington Gazette unrolls the science.
What is actually approved, and when it happened
The phrase "gene therapy for skin disease" has spent two decades in the future tense. It is not there any more, and the change happened in stages that were easy to miss unless you were watching a rare disease.
In May 2023 the FDA approved beremagene geperpavec, marketed as Vyjuvek, for patients six months and older with dystrophic epidermolysis bullosa — the first redosable gene therapy of any kind, and one applied topically to wounds. The European Commission followed in April 2025, granting marketing authorisation for patients from birth, with dosing permitted at home rather than only in a clinic.
A week later, on 29 April 2025, the FDA approved prademagene zamikeracel, marketed as Zevaskyn, for recessive dystrophic epidermolysis bullosa. It works nothing like the first one: a patient's own skin cells are gene-corrected in a laboratory, grown into sheets, and surgically applied to large chronic wounds in a single procedure.
So within twenty-four months, one disease acquired two approved gene therapies using two entirely different delivery philosophies. That is unusual, and it is not an accident of funding.
Why this disease went first
Dystrophic epidermolysis bullosa is caused by mutations in COL7A1, the gene encoding type VII collagen. Type VII collagen forms anchoring fibrils — the structures that fasten the epidermis to the dermis underneath it. Without them the two layers separate under ordinary mechanical stress, so skin blisters and tears from friction that would not mark anyone else. The result is large, chronic, painful wounds, and a lifetime of dressing changes.
Every feature of that description is what makes a disease tractable for a first attempt. It is monogenic, so there is one gene to deliver rather than a network to modulate. The missing protein is structural and locally acting, so it does not need to reach a distant organ or be regulated minute to minute. The affected tissue is on the outside of the body, which means the drug can be applied directly rather than dosed systemically and hoped for. And the endpoint is visible: a wound is either closed or it is not, and it can be photographed.
Compare that with almost any other genetic disease and the appeal is obvious. Skin was not chosen because epidermolysis bullosa is common — it is rare. It was chosen because skin is the organ where you can see whether it worked.
Two ways to get a gene into skin
The topical approach uses a herpes simplex virus type 1 vector, engineered to be replication-incompetent, carrying two functional copies of COL7A1. It is applied to wounds weekly. The virus enters keratinocytes and fibroblasts, the cell reads the delivered gene, and it manufactures type VII collagen locally.
The design choice that matters most is that the vector does not integrate into the genome. That removes a category of risk that has historically shadowed gene therapy — and it comes with an equally important consequence. Because it does not integrate, and because skin cells turn over, the effect fades. The therapy has to be reapplied indefinitely. "Redosable" reads as a convenience feature in a press release; it is really an admission built into the mechanism.
The grafted approach solves the same problem from the opposite direction. Cells are taken from the patient, corrected outside the body with a retroviral vector that does integrate, expanded into sheets, and sutured onto a wound in one surgical session. One intervention, durable in the grafted area, limited to the area grafted — a maximum of six wounds per patient in the trial. Neither is better in the abstract. They address different wound problems: weekly maintenance across many small lesions, versus one-time repair of a few large chronic ones.
What the trials showed, and where the benefit stops
The numbers are strong, and the honest reading requires holding two things at once.
The phase 3 trial of the topical therapy, published in the New England Journal of Medicine in 2022, enrolled 31 patients and used an intrapatient design: for each patient, a matched pair of wounds was randomised, one to active treatment and one to placebo. At six months, 67% of treated wounds had healed completely against 22% of placebo wounds — a 46-percentage-point difference. At three months it was 71% against 20%.
The grafted therapy's phase 3 trial, VIITAL, published in The Lancet in 2025, enrolled 11 patients with 43 randomised wound pairs, all wounds larger than 20 cm². At 24 weeks, 35 of 43 treated wounds (81%) were at least half healed, against 7 of 43 controls (16%). Wound pain fell by 3.07 points against 0.90 in controls. No serious treatment-related adverse events were reported.
Now the limits, which the papers state plainly and the coverage often does not. Both trials measured wounds, not people — the unit of success is a lesion, and a patient with epidermolysis bullosa has many. In the topical trial, the pain benefit was far more modest than the healing benefit: an adjusted mean difference of about 0.61 points on a ten-point scale during dressing changes. The grafted therapy is capped by surgical practicality. And the enrolled populations are tiny, because the disease is rare.
This is a real and substantial improvement in wound burden. It is not a cure for the underlying condition, and nobody involved has claimed otherwise.
Why skin is the favourable organ — and what that opens up
The intrapatient design used in both trials deserves attention beyond dermatology, because it is a luxury the anatomy grants.
When the target tissue is accessible and lesions are numerous, a single patient can carry both the treatment and its control. That eliminates the between-person variability that makes small rare-disease trials so difficult to interpret. Eleven patients produced 43 randomised pairs. You cannot randomise two halves of a liver.
The generalisation is already underway. In October 2025 the FDA granted platform technology designation to the HSV-1 vector used in this approach — a mechanism intended to let an established delivery system carry regulatory and manufacturing groundwork forward into new programmes rather than starting over each time. Candidates using the same vector are in trials for corneal abrasions in dystrophic epidermolysis bullosa, delivered as eye drops, and for respiratory conditions delivered by inhalation. Skin was the proving ground, not the destination.
A necessary deflation, though: none of this is heading toward cosmetic dermatology. These are corrective therapies for single-gene disorders with a missing structural protein, priced and regulated accordingly. Photoageing is not a gene you can replace, and there is no version of this that becomes a serum.
For everyone whose skin makes its own type VII collagen, the relevant layer remains symptomatic and mechanical: occlusion and barrier support with petrolatum-based ointments like Aquaphor Healing Ointment or CeraVe Healing Ointment, and ceramide-led repair creams such as CeraVe Moisturizing Cream — the same category that supports wound care in epidermolysis bullosa alongside these therapies rather than instead of them. Barrier-repair options for compromised skin covers that ground.
What has genuinely changed is the tense. For a specific group of patients, the sentence "there is a treatment that addresses the cause" is now true, and the evidence supporting it was produced to a standard that most rare diseases never reach. Anyone navigating a diagnosis like this into a specialist appointment will find the derm visit prep tool useful for turning that literature into a written list of questions rather than a half-remembered headline.
References
- Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa — New England Journal of Medicine, 2022
- Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial — The Lancet, 2025
- Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa — Annals of Medicine and Surgery, 2023
Every cited link is verified to resolve to the paper named. Where a source could not be independently confirmed, it is listed without a link rather than pointing you somewhere wrong.
Frequently asked
Is this a cure for epidermolysis bullosa?
No, and neither developer claims it is. The topical therapy delivers a non-integrating vector, so its effect fades as skin cells turn over and it must be reapplied indefinitely. The grafted therapy is durable but limited to the wounds actually treated — a maximum of six per patient in the trial. Both reduce wound burden substantially without correcting the underlying genotype.
How well did the topical gene therapy actually work?
In a 31-patient phase 3 trial, matched wound pairs within each patient were randomised to treatment or placebo. At six months, 67% of treated wounds had healed completely versus 22% of placebo wounds. Pain relief was far more modest, with an adjusted mean difference of roughly 0.61 points on a ten-point scale during dressing changes.
Why did gene therapy reach skin before other organs?
Because dystrophic epidermolysis bullosa is monogenic, the missing protein acts structurally and locally, the tissue can be dosed topically without systemic exposure, and wound closure is a visible endpoint. Skin also permits intrapatient control designs — one person carries both treated and untreated wounds — which delivers unusual statistical power from very small trials.
Will this technology reach ordinary skincare?
No. These are corrective therapies for single-gene disorders with a defined missing protein, and they are regulated and priced as such. Ageing, pigmentation and acne are not single-gene deficiencies, so there is no path by which this becomes a cosmetic serum. The realistic expansion is into other rare monogenic conditions and other accessible tissues.
Each shelf lists every product in the catalogue built on the ingredient, graded live against your profile — the shelf stays current when a single pick would not.
Products named in this piece
Independently reviewed, with a verdict per concern — the real products behind this piece.